Vertex joins Merck, Pfizer — revamping multibillion-dollar trial strategy as biotech R&D crumbles
You can add Pfizer, Merck and — as we found out Friday morning — Vertex to the growing list of pharma giants hitting the pause button on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
